Heximar Ointment contains calcipotriol as its active component. Calcipotriol is a synthetic analogue of vitamin D 3 that is applied to the skin to treat certain inflammatory skin conditions. The product is supplied in a tube formulation in two strengths: 15 g and 30 g. In Hong Kong, Heximar Ointment is classified as a prescription-only (Rx) topical medication and is regulated by the Department of Health’s Pharmacy and Poisons Board.
Calcipotriol exerts its therapeutic effect by binding to the vitamin D receptor (VDR) on keratinocytes, the predominant cell type in the epidermis. Activation of the VDR leads to:
These actions together help to normalise the thickness and scaling of psoriatic plaques. The medication is applied topically, so systemic absorption is minimal; most of the drug remains within the epidermal layers where it can act directly on VDR.
Heximar Ointment is approved in Hong Kong for the topical treatment of plaque psoriasis in adults. The indication includes:
The product is not indicated for other skin disorders unless supported by a clinician’s clinical judgment.
If any of these conditions apply, clinicians may choose alternative therapy.
These reactions are usually transient and improve with continued use or by reducing the amount applied.
If any severe symptoms develop, treatment should be stopped and medical evaluation sought promptly.
Topical calcipotriol has limited systemic exposure; therefore, drug-drug interactions are uncommon. However:
Patients should disclose all prescription, over-the-counter, and herbal products to their healthcare provider before initiating Heximar Ointment.
This article provides educational information about Heximar Ointment and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Heximar Ointment may be applied to facial plaques if a dermatologist determines it is appropriate, but the skin on the face is more prone to irritation. A lower amount and careful monitoring are recommended.
Mild redness can be a normal initial reaction. If redness intensifies, becomes painful, or is accompanied by swelling, discontinue use and seek medical evaluation to rule out an allergic response.
Concurrent use of a topical corticosteroid with calcipotriol is a common therapeutic strategy and can improve efficacy. The combination should be prescribed and monitored by a healthcare professional to avoid excessive skin thinning.
The duration depends on the total body surface area treated and the thickness of the application. For most patients applying a thin layer to limited plaques, a 15 g tube may last several weeks to a few months.
Yes, Heximar Ointment is classified as a prescription-only medication in Hong Kong and must be obtained from a licensed pharmacy with a valid prescription.
Calcipotriol is categorized as pregnancy category C, indicating limited safety data. Use during pregnancy is permitted only if the potential benefits justify the potential risks to the fetus, and this decision should be made by a treating physician.
Both contain the same active ingredient, but ointments generally provide a more occlusive barrier, potentially enhancing skin hydration. Creams may feel less greasy and be preferred for larger or less thickened areas. Efficacy is comparable when used as directed.
Topical use typically results in minimal systemic absorption, so routine blood work is unlikely to be affected. However, clinicians may order serum calcium tests periodically to monitor for rare systemic effects.
Heximar Ointment can be carried in hand luggage, but the tube should be placed in a clear, resealable plastic bag if the flight is subject to liquid restrictions. No special permits are required for personal medical use.
Heximar Ointment is a topical agent targeting skin lesions directly, while biologics act systemically to modulate immune pathways. Topical therapy is typically first-line for mild-to-moderate disease, whereas biologics are reserved for moderate-to-severe cases unresponsive to topical or phototherapy options.
